A report on process intensification highlights persistent misconceptions that can slow adoption of advanced manufacturing and development workflows. The piece—citing a survey of more than 150 life science veterans conducted with Thermo Fisher Scientific and BioPharma Dive—focuses on regulatory and operational concerns, along with how teams can translate intensification goals into measurable gains. The report challenges the belief that process intensification inherently triggers regulatory scrutiny, pointing to FDA acknowledgment of advanced manufacturing techniques and describing guidance around activities such as real-time release. It also emphasizes engaging regulatory and quality experts early to avoid defaulting to incumbent processes. The editorial framing suggests that execution planning and regulatory alignment are now central to realizing benefits from faster, more efficient manufacturing strategies.